Human cathelicidin peptide studied for antimicrobial activity, immune modulation, wound healing, and anti-biofilm support. Physician-reviewed. Prescription required.
LL-37 is a human cathelicidin antimicrobial peptide studied for immune modulation, antimicrobial activity, wound healing, and anti-biofilm properties. It supports the body's natural immune defenses and tissue repair processes.
LL-37 is the only cathelicidin antimicrobial peptide produced by humans. It is a 37-amino acid peptide derived from the inactive precursor hCAP18 (human cationic antimicrobial protein 18), found in neutrophils, macrophages, and epithelial cells. LL-37 is a key component of the innate immune system.
LL-37 has multiple roles in immune defense and tissue health. It exhibits direct antimicrobial activity against bacteria, viruses, and fungi through disruption of microbial membranes. Additionally, it modulates immune responses, promotes wound healing, prevents biofilm formation, and supports tissue repair through enhanced growth factor signaling.
Research demonstrates that LL-37 levels are often depleted in chronic inflammatory conditions, infections, and wounds. Restoration of LL-37 levels is being investigated as a therapeutic strategy to enhance immune function, improve antimicrobial defenses, and accelerate healing.
Direct Antimicrobial Activity: LL-37 kills microorganisms through several mechanisms: it disrupts bacterial and fungal cell membranes through its cationic, amphipathic structure; it inhibits biofilm formation and disrupts established biofilms; and it shows broad-spectrum activity against Gram-positive and Gram-negative bacteria, fungi, and certain enveloped viruses.
Immune Modulation: LL-37 activates innate immune cells (neutrophils, macrophages, dendritic cells) through pattern recognition receptor signaling. It enhances chemotaxis, promoting immune cell recruitment to sites of infection or inflammation. It also modulates inflammatory responses, promoting resolution of infection and prevention of excessive inflammation.
Wound Healing & Tissue Repair: LL-37 promotes angiogenesis (new blood vessel formation), enhances fibroblast function, and stimulates epithelial cell growth and migration. It supports collagen deposition and tissue remodeling through growth factor signaling, particularly VEGF and TGF-β pathways.
Anti-inflammatory & Anti-biofilm: Beyond direct antimicrobial effects, LL-37 prevents pathogenic biofilm formation, disrupts existing biofilms (making embedded microorganisms accessible to antibiotics), and resolves chronic inflammatory states associated with persistent infections.
Research Context: LL-37 has been extensively studied in basic and clinical research for its multifaceted immunological properties. Low LL-37 levels correlate with chronic infections, poor wound healing, and inflammatory diseases.
Not a candidate? During your physician consultation, your medical history, immune status, current infections, and health goals will be evaluated. LL-37 may not be appropriate if you have certain autoimmune conditions or other contraindications. Your physician will determine suitability.
LL-37 is not FDA-approved as a finished drug product. It is dispensed as a compounded medication through licensed 503A compounding pharmacies. A valid physician prescription is required before any order can be filled. All Verum Health protocols require a clinical consultation and physician approval.
LL-37 is typically administered as a subcutaneous injection in 5MG/ML concentration (5ML vial). Exact dosing and injection frequency will be determined during your physician consultation based on your individual needs, immune status, infection severity, and treatment goals. Standard protocols typically range from 1-3 mg per dose, 1-3 times weekly.
Follow-up assessments may include immune markers (white blood cell count, inflammatory markers), LL-37 serum levels, microbial cultures, and clinical assessment of infection status or wound healing. Your physician will schedule check-ins to assess efficacy, tolerability, and adjust dosing as needed. Reorders require physician approval based on lab results and clinical outcomes.